摩根士丹利发表研究报告指，预期华润医疗上半年净利润将录得轻微增长。由于按疾病诊断相关分组(DRG)和按病种分值(DIP)两种医保支付方式的压力持续，预期基本业务利润将出现高双位数的按年下降。同时，该行将诉讼和解的一次性收益2.09亿元计算在内。大摩上调华润医疗今年每股盈测5%，但对2026及27年每股盈测分别下调8%和4%，目标价由3.3港元降至3港元，维持“减持”评级。
摩根士丹利发表研究报告指，预期华润医疗上半年净利润将录得轻微增长。由于按疾病诊断相关分组(DRG)和按病种分值(DIP)两种医保支付方式的压力持续，预期基本业务利润将出现高双位数的按年下降。同时，该行将诉讼和解的一次性收益2.09亿元计算在内。大摩上调华润医疗今年每股盈测5%，但对2026及27年每股盈测分别下调8%和4%，目标价由3.3港元降至3港元，维持“减持”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.